Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 15/20 | 0.64 |
| ▸ | JAK1 | P23458 | 12/20 | 0.64 |
| ▸ | JAK2 | O60674 | 12/20 | 0.64 |
| ▸ | TYK2 | P29597 | 3/20 | 0.57 |
| ▸ | TTK | P33981 | 2/20 | 0.57 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.51 |
| ▸ | FLT4 | P35916 | 1/20 | 0.50 |
| ▸ | STAT6 | P42226 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16782603 | 0.91 | JAK3 (0.62) | JAK3JAK1JAK2TYK2TTK | |
| SCHEMBL16782466 | 0.90 | JAK3 (0.65) | JAK3JAK1JAK2TYK2ALK | |
| SCHEMBL16782468 | 0.90 | JAK3 (0.64) | JAK3JAK1JAK2TYK2ALK | |
| SCHEMBL15560951 | 0.88 | JAK3 (0.70) | JAK3JAK1JAK2TYK2STAT6 | |
| SCHEMBL15560706 | 0.88 | JAK3 (0.65) | JAK3JAK1JAK2TYK2STAT6 | |
| SCHEMBL15547080 | 0.87 | JAK3 (0.61) | JAK3JAK1JAK2TYK2ALK | |
| SCHEMBL15545659 | 0.87 | JAK3 (0.61) | JAK3JAK1JAK2TYK2ALK | |
| SCHEMBL15560314 | 0.86 | JAK3 (0.63) | JAK3JAK1JAK2TYK2ALK | |
| SCHEMBL15548247 | 0.86 | JAK1 (0.60) | JAK3JAK1JAK2TYK2ALK | |
| SCHEMBL16782598 | 0.86 | JAK2 (0.72) | JAK3JAK1JAK2TYK2TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2855451-B1 | HETEROCYCLYL PYRIMIDINE ANALOGUES AS TYK2 INHIBITORS | CELLZOME LTD (GB) | 2017-10-04 | — | — | EP | claimed |
| US-9655897-B2 | Heterocyclyl pyrimidine analogues as TYK2 inhibitors | CELLZOME LIMITED (GB) | 2017-05-23 | — | — | US | claimed |
| US-20160184307-A1 | Heterocyclyl Pyrimidine Analogues As TYK2 Inhibitors | CELLZOME LIMITED (GB) | 2016-06-30 | — | — | US | claimed |
| US-9296725-B2 | Heterocyclyl pyrimidine analogues as TYK2 inhibitors | CELLZOME LIMITED (GB) | 2016-03-29 | — | — | US | claimed |
| US-20150166513-A1 | Heterocyclyl Pyrimidine Analogues As TYK2 Inhibitors | CELLZOME LIMITED (GB) | 2015-06-18 | — | — | US | claimed |
| EP-2855451-A1 | HETEROCYCLYL PYRIMIDINE ANALOGUES AS TYK2 INHIBITORS | Cellzome Limited (GB) | 2015-04-08 | — | — | EP | claimed |
| WO-2013174895-A1 | HETEROCYCLYL PYRIMIDINE ANALOGUES AS TYK2 INHIBITORS | CELLZOME LIMITED (GB) | 2013-11-28 | — | — | WO | claimed |
| EP-2855451-B1 | HETEROCYCLYL PYRIMIDINE ANALOGUES AS TYK2 INHIBITORS | CELLZOME LTD (GB) | 2017-10-04 | — | — | EP | disclosed |
| EP-2855451-B1 | HETEROCYCLYL PYRIMIDINE ANALOGUES AS TYK2 INHIBITORS | CELLZOME LTD (GB) | 2017-10-04 | — | — | EP | disclosed |
| US-9655897-B2 | Heterocyclyl pyrimidine analogues as TYK2 inhibitors | CELLZOME LIMITED (GB) | 2017-05-23 | — | — | US | disclosed |
| US-9655897-B2 | Heterocyclyl pyrimidine analogues as TYK2 inhibitors | CELLZOME LIMITED (GB) | 2017-05-23 | — | — | US | disclosed |
| US-9655897-B2 | Heterocyclyl pyrimidine analogues as TYK2 inhibitors | CELLZOME LIMITED (GB) | 2017-05-23 | — | — | US | disclosed |
| US-20160184307-A1 | Heterocyclyl Pyrimidine Analogues As TYK2 Inhibitors | CELLZOME LIMITED (GB) | 2016-06-30 | — | — | US | disclosed |
| US-20150166513-A1 | Heterocyclyl Pyrimidine Analogues As TYK2 Inhibitors | CELLZOME LIMITED (GB) | 2015-06-18 | — | — | US | disclosed |
| US-20150166513-A1 | Heterocyclyl Pyrimidine Analogues As TYK2 Inhibitors | CELLZOME LIMITED (GB) | 2015-06-18 | — | — | US | disclosed |
| US-20150166513-A1 | Heterocyclyl Pyrimidine Analogues As TYK2 Inhibitors | CELLZOME LIMITED (GB) | 2015-06-18 | — | — | US | disclosed |
| EP-2855470-A1 | NOVEL BICYCLIC THIAZOLE COMPOUNDS | Carna Biosciences Inc. (JP) | 2015-04-08 | — | — | EP | disclosed |
| EP-2855451-A1 | HETEROCYCLYL PYRIMIDINE ANALOGUES AS TYK2 INHIBITORS | Cellzome Limited (GB) | 2015-04-08 | — | — | EP | disclosed |
| WO-2013176293-A1 | NOVEL BICYCLIC THIAZOLE COMPOUNDS | CARNA BIOSCIENCES, INC. (JP) | 2013-11-28 | — | — | WO | disclosed |
| WO-2013174895-A1 | HETEROCYCLYL PYRIMIDINE ANALOGUES AS TYK2 INHIBITORS | CELLZOME LIMITED (GB) | 2013-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166513-A1 | Heterocyclyl Pyrimidine Analogues As TYK2 Inhibitors | TYK2, TXK, IRAK1 | JAK3 15/4885JAK1 6/4885JAK2 10/4885 |
| US-20160184307-A1 | Heterocyclyl Pyrimidine Analogues As TYK2 Inhibitors | TYK2, TXK, IRAK1 | JAK3 15/4885JAK1 6/4885JAK2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.